News

The study added to the evidence base for recommending adherence to treatment with disease-modifying therapies in clinical practice, a key element for reducing moderate or severe relapse rate.

With the first approved biosimilar entering the US treatment market, the time for clinicians to understand the coming era of therapies is now.

Neurology News Network for the week ending November 25, 2023. [WATCH TIME: 4 minutes

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 24, 2023.

Apart from the small pump system, which was preferred by the patients, the study found no clear advantage of levodopa-entacapone-carbidopa to levodopa-carbidopa intestinal gel.

The effect of gaslighting on patients can result in serious harms, and although it is potentially common in the MS care continuum, whether it is deliberate or an institutional problem, it must be called out by providers.

We are closer than ever to individualized management of MS, and keeping up with the rapidly changing pace of MS care is challenging even for an MS specialist.

Rebecca Whitney, associate director of Programs and Community Support at SRNA and mother of child with a rare neuroimmune disorder, provided thoughts on the importance of caregivers and the role they play in everyday life.

The associate professor of clinical neurology at University of Miami Miller School of Medicine discussed the implications of findings from a recent post hoc analysis on midazolam and the need for inclusive research in assessing the efficacy of seizure rescue treatments. [WATCH TIME: 3 minutes]

The director of the Banner Sun Health Research Institute provided commentary on his presentation at CTAD 2023 examining the value of donanemab and its effect on specific Alzheimer-related assessments. [WATCH TIME: 10 minutes]

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center discussed RNDS 2023, an educational event for Spanish-speaking patients with rare neuroimmune disorders.

Pixyl.Neuro, a CE-marked medical device, is designed to be integrated into the radiology workflow, providing clinicians with diagnostic support of neuroinflammatory and neurodegenerative disorders.

The FDA has scheduled an in-person meeting for December 6th to discuss the regulatory path for BrainStorm Cell Therapeutics’ NurOwn as a potential treatment for patients with amyotrophic lateral sclerosis.

The associate professor of clinical neurology at the University of Miami Miller School of Medicine talked about findings from a recent post hoc analysis assessing the FDA-approved treatment of midazolam for seizure clusters. [WATCH TIME: 3 minutes]

In a phase 2 study, sodium oxybate showed a significant, albeit short-lived, reduction in voice symptoms for patients with alcohol-responsive essential tremor of voice.

Ahead of the 2024 MDA Conference, the vice president of public policy and advocacy at the Muscular Dystrophy Association talked about conference advocacy collaboration, access to treatments, and the state of healthcare. [WATCH TIME: 6 minutes]

A recently published study revealed that speech markers can have a high accuracy in distinguishing between neurodegenerative diseases and healthy speech, emphasizing the significance of speech analysis in disease assessment.

A recent study conducted across 11 centers globally challenged the assumption that cognitive rehabilitation and exercise synergistically benefit patients with progressive multiple sclerosis.

The double-blind, placebo-controlled study is expected to include 9 patients aged 35-75 years old with MSA-parkinsonian type who will be randomized 2:1 to either investigational AB-1005 or sham surgery.

The interim chief of pediatric neurology at Stanford Medicine Children’s Health provided insight on advances the screening for epilepsy surgery and the factors that pediatric neurologists should consider. [WATCH TIME: 5 minutes]

Insurance coverage or cost was considered a barrier to prescribing novel NMOSD treatments in 42% of respondents, with the highest rate seen in eculizumab.

Here's some of what is coming soon to NeurologyLive® this week.

A recent study suggests that palliative education and telehealth improve quality of life and advance care planning among patients with Parkinson disease and related disorders.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

If successful, the study has potential implications for future surgical outcomes and patient experience among those with Parkinson disease.

A recently published questionnaire study showed that certain health symptoms affected epilepsy-specific health-related quality of life beyond sociodemographic and epilepsy characteristics according to responses from both caregivers and pediatric patients.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 17, 2023.

The director of disability policy at the Muscular Dystrophy Association talked about the future possibility of having an aircraft that accommodates for patients with neuromuscular disorders who use mobility devices. [WATCH TIME: 3 minutes]